Jiyoutai (semaglutide SC once-weekly biosimilar) / Huadong Medicine - LARVOL DELTA

Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes (clinicaltrials.gov) - P3 | N=494 | Completed | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

HDG1901-103: Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. (clinicaltrials.gov) - P1 | N=68 | Completed | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients (clinicaltrials.gov) - P3 | N=460 | Recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P3 trial • Genetic Disorders • Obesity

Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial (ADA 2025) - P3 | "In patients with T2D, HDG1901 was equivalent to reference semaglutide with respect to the mean changes from baseline in HbA1c at 32 weeks. HDG1901 was generally well tolerated in this population. It offers an option for the treatment of T2D (ClinicalTrials.gov identifier: NCT06739044)."

Clinical • P3 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Semaglutide Injection Vs Ozempic® in Patients with Type 2 Diabetes (clinicaltrials.gov) - P3 | N=494 | Active, not recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus